What is the recommended diagnostic workup and management for mast cell activation syndrome?

Mast Cell Activation Syndrome: Diagnostic Workup and Management

Diagnostic Approach

Begin with the three consensus diagnostic criteria: (1) episodic symptoms typical of mast cell activation involving at least two organ systems, (2) objective biochemical evidence of mast cell mediator release, and (3) clinical response to antimediator therapy. 1, 2

Clinical Presentation

The prototypical presentation is idiopathic anaphylaxis with severe, episodic symptoms rather than chronic daily complaints 3. Look specifically for:

• Dermatologic: Flushing, pruritus, urticaria 1
• Cardiovascular: Tachycardia, hypotension, syncope 1, 3
• Respiratory: Bronchospasm, wheezing, throat swelling 1
• Gastrointestinal: Abdominal cramping, diarrhea, nausea 1
• Neurologic: Headache, brain fog 1

Symptoms must be episodic and severe, not merely chronic low-grade complaints, and involve at least two organ systems 3, 2.

Biochemical Confirmation

The gold standard is demonstrating an acute increase in serum tryptase during a symptomatic episode (drawn within 4 hours) compared to baseline, defined as >20% + 2 ng/mL above baseline. 2, 3

Critical pitfall: Elevated baseline tryptase alone does NOT diagnose MCAS, nor do normal values exclude it 3. You must document the acute rise during symptoms.

Alternative biochemical markers when serum tryptase is unavailable 3, 4:

• Urinary N-methylhistamine (histamine metabolite)
• Urinary leukotriene E4 (cysteinyl leukotriene metabolite)
• Urinary 2,3-dinor-11β-prostaglandin F2α (prostaglandin D2 metabolite)

Collect baseline urine samples and compare to specimens obtained 3-6 hours post-episode 3. These can be collected at home, making them more practical than serum tryptase during acute events 4.

Exclude Secondary Causes

Before diagnosing primary MCAS, rule out 3, 5:

• IgE-mediated allergies (particularly cofactor-dependent food allergy)
• NSAID hypersensitivity
• Physical urticarias
• Other systemic conditions mimicking mast cell activation

Evaluate for Clonal Mast Cell Disorders

In patients meeting MCAS criteria, especially those with idiopathic anaphylaxis, assess for underlying systemic mastocytosis 3, 2:

• Baseline serum tryptase (persistently >20 ng/mL suggests clonal disease) 3
• KIT p.D816V mutation testing in peripheral blood using high-sensitivity assays 3
• Spanish Network on Mastocytosis score to predict probability of clonal disease 2
• Bone marrow biopsy if high probability of mast cell clonality 3

---

Management Strategy

Acute Episode Management

All patients with history of systemic anaphylaxis or airway angioedema must be prescribed an epinephrine autoinjector and trained on its use. 1

Additional acute interventions 1:

• Supine positioning immediately for hypotensive episodes (use bedpan for diarrhea, emesis basin after rolling to side)
• Albuterol via nebulizer or metered-dose inhaler for bronchospasm
• Corticosteroids for prolonged episodes (though not first-line for acute anaphylaxis)

Prophylactic Therapy: Stepwise Approach

Start with second-generation H1-antihistamines (fexofenadine or cetirizine) at 2-4 times FDA-approved doses, combined with H2-antihistamines (famotidine or cimetidine). 1

The rationale: H1 and H2 receptor antagonists work prophylactically by blocking histamine binding before symptoms develop, not as acute treatment once mediators are already released 1.

Avoid first-generation H1-antihistamines (diphenhydramine, hydroxyzine) in elderly patients due to cognitive decline risk and anticholinergic effects, particularly concerning in MCAS patients prone to cardiovascular events. 1

Step-Up Therapy for Refractory Symptoms

Add sequentially as needed 1:

• Leukotriene modifiers (montelukast or zileuton) for bronchospasm or gastrointestinal symptoms, especially if urinary LTE4 elevated
• Cromolyn sodium to inhibit mediator release
• Cyproheptadine for gastrointestinal symptoms (dual H1-blocker and serotonin antagonist)
• Aspirin (if tolerated) to inhibit prostaglandin synthesis
• Omalizumab for prevention of recurrent anaphylaxis in select cases
• Corticosteroid burst (0.5 mg/kg/day with slow taper over 1-3 months) for refractory symptoms, though long-term use limited by side effects

Procedural Prophylaxis

For patients with problematic mast cell activation during radiologic or invasive procedures, give prednisone 50 mg at 13 hours, 7 hours, and 1 hour before the procedure. 1

Important Caveats

• Ketotifen (compounded tablets in US) is used for dermatologic, gastrointestinal, and neuropsychiatric symptoms, but evidence it outperforms other antihistamines is lacking 1
• H2-blockers and anticholinergic H1-blockers carry cognitive decline risk, especially in elderly populations 1
• Most therapeutic recommendations are based on expert opinion and case series rather than controlled trials 1